| 4645 |
Role of a DTO |
07/06/2024 |
Training and HR Development |
| 4821 |
Training and capacity development |
07/06/2024 |
Training and HR Development |
| 4822 |
The NTEPs Training System |
07/06/2024 |
Training and HR Development |
| 4823 |
Planning the training |
07/06/2024 |
Training and HR Development |
| 4824 |
The LMS- Swasth-eGurukul |
07/06/2024 |
Training and HR Development |
| 4825 |
Operationalising the training |
07/06/2024 |
Training and HR Development |
| 4826 |
Monitoring of Trainings |
07/06/2024 |
Training and HR Development |
| 4827 |
Role and Responsibilities of key Stakeholders |
07/06/2024 |
Training and HR Development |
| 5264 |
National Medical Commission: Code of Ethics |
07/06/2024 |
Training and HR Development |
| 5265 |
Gazette on Ban of Serological Tests for diagnosis of TB |
07/06/2024 |
Training and HR Development |
| 5266 |
Schedule H1 – Drugs & Cosmetics Act, 1940 |
07/06/2024 |
Training and HR Development |
| 5629 |
Role of a PPM coordinator |
07/06/2024 |
Training and HR Development |
| 5691 |
Pulmonary TB |
07/06/2024 |
Training and HR Development |
| 6436 |
Heat sensitivity of BCG Vaccine |
11/06/2024 |
TB prevention including airborne infection control |
| 6437 |
Open vial policy for BCG vaccine |
11/06/2024 |
TB prevention including airborne infection control |
| 6233 |
Wastage rate of BCG Vaccine |
11/06/2024 |
TB prevention including airborne infection control |
| 6234 |
Placement of BCG Vaccine at the vaccination site |
11/06/2024 |
TB prevention including airborne infection control |
| 6236 |
Reverse cold chain for BCG Vaccine |
11/06/2024 |
TB prevention including airborne infection control |
| 6237 |
Recording of BCG vaccine stock & issue |
11/06/2024 |
TB prevention including airborne infection control |
| 6453 |
Adult BCG Vaccine- DO’s for injection safety |
11/06/2024 |
TB prevention including airborne infection control |
| 6454 |
Adult BCG Vaccine- Don’t's for injection safety |
11/06/2024 |
TB prevention including airborne infection control |
| 6467 |
Overview of presentation |
11/06/2024 |
|
| 6178 |
AEFI reporting formats - serious/severe |
11/06/2024 |
TB prevention including airborne infection control |
| 6473 |
Adult BCG Vaccine-Precautions to be taken to minimize AEFI |
11/06/2024 |
TB prevention including airborne infection control |
| 6190 |
Very rare AEFIs reported with BCG Vaccine |
11/06/2024 |
TB prevention including airborne infection control |
| 6191 |
Other potential AEFI post BCG vaccine |
11/06/2024 |
TB prevention including airborne infection control |
| 6474 |
Handling of anaphylaxis post BCG vaccine |
11/06/2024 |
TB prevention including airborne infection control |
| 6184 |
Difference between anaphylaxis kit and AEFI kit |
11/06/2024 |
TB prevention including airborne infection control |
| 6185 |
Managing serious and severe AEFIs post BCG vaccine |
11/06/2024 |
TB prevention including airborne infection control |
| 6475 |
Adult BCG Vaccine-Reporting of AEFI |
11/06/2024 |
TB prevention including airborne infection control |
